In line with this, an in vitro study in breast cancer suggested that the combination with IL-2 or IL-15 could boost the lytic activity against tumor cells, therefore augmenting the therapeutic efficacy of Avelumab [120]. This evidence concerns the gene IL2 and neoplasm.